SCHEMBL2222302

SCHEMBL2222302

CC(C)(C)NC(=O)CC1CCN(c2ccccc2NC(=O)c2cccc(Cl)c2)CC1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.61
KMT2A Q03164 3/20 0.61
CYP1A2 P05177 1/20 0.57
CYP3A4 P08684 1/20 0.57
CYP2D6 P10635 1/20 0.57
CYP2C9 P11712 1/20 0.57
CYP2C19 P33261 1/20 0.57
CACNA1H O95180 2/20 0.49
KCNH2 Q12809 1/20 0.48
CACNA1I Q9P0X4 1/20 0.48
CXCR3 P49682 2/20 0.47
KCNQ2 O43526 2/20 0.47
GFER P55789 1/20 0.47
LMNA P02545 1/20 0.46
MAPT P10636 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
GAA P10253 1/20 0.46
TSHR P16473 2/20 0.46
HSD17B10 Q99714 1/20 0.46
MAPK1 P28482 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12516603 0.86 KMT2A (0.69) MEN1KMT2ACYP1A2CYP3A4CYP2D6
SCHEMBL2266970 0.84 CXCR3 (0.64) MEN1KMT2ACYP1A2CYP3A4CYP2D6
SCHEMBL2224642 0.83 NPSR1 (0.53) MEN1KMT2ACYP1A2CYP2D6CYP2C19
SCHEMBL12516604 0.83 MEN1 (0.61) MEN1KMT2ACYP1A2CYP3A4CYP2D6
SCHEMBL2222549 0.81 CXCR3 (0.59) MEN1KMT2ACYP1A2CYP3A4CYP2D6
SCHEMBL2269026 0.81 TRPV1 (0.48) CACNA1HKCNH2CACNA1ICXCR3GAA
SCHEMBL2224011 0.80 CXCR3 (0.45) MEN1KMT2ACACNA1HKCNH2CACNA1I
SCHEMBL2270318 0.80 CXCR3 (0.45) MEN1KMT2ACYP1A2CYP3A4CYP2D6
SCHEMBL2221486 0.80 MEN1 (0.72) MEN1KMT2ACYP1A2CYP3A4CYP2D6
SCHEMBL2223364 0.80 CXCR3 (0.53) MEN1KMT2ACACNA1HKCNH2CACNA1I

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130029971-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-01-31 US claimed
WO-2011084985-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-07-14 WO claimed
US-8952004-B2 CXCR3 receptor antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-02-10 US disclosed
US-8952004-B2 CXCR3 receptor antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-02-10 US disclosed
US-20130029971-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-01-31 US disclosed
US-20130029971-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-01-31 US disclosed
WO-2011084985-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-07-14 WO disclosed
WO-2011084985-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-07-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130029971-A1 CXCR3 RECEPTOR ANTAGONISTS CXCR3, CXCR1, CXCR2 MEN1 3640/4885KMT2A 3936/4885CYP1A2 2248/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.